Cargando…

High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region

BACKGROUND: Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains are a serious health problem in India, also contributing to one-fourth of the global MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fluoroquinolone (FQ) resistant leading to high pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreyer, Viola, Mandal, Ayan, Dev, Prachi, Merker, Matthias, Barilar, Ivan, Utpatel, Christian, Nilgiriwala, Kayzad, Rodrigues, Camilla, Crook, Derrick W., Rasigade, Jean-Philippe, Wirth, Thierry, Mistry, Nerges, Niemann, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394022/
https://www.ncbi.nlm.nih.gov/pubmed/35989319
http://dx.doi.org/10.1186/s13073-022-01076-0
_version_ 1784771397285838848
author Dreyer, Viola
Mandal, Ayan
Dev, Prachi
Merker, Matthias
Barilar, Ivan
Utpatel, Christian
Nilgiriwala, Kayzad
Rodrigues, Camilla
Crook, Derrick W.
Rasigade, Jean-Philippe
Wirth, Thierry
Mistry, Nerges
Niemann, Stefan
author_facet Dreyer, Viola
Mandal, Ayan
Dev, Prachi
Merker, Matthias
Barilar, Ivan
Utpatel, Christian
Nilgiriwala, Kayzad
Rodrigues, Camilla
Crook, Derrick W.
Rasigade, Jean-Philippe
Wirth, Thierry
Mistry, Nerges
Niemann, Stefan
author_sort Dreyer, Viola
collection PubMed
description BACKGROUND: Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains are a serious health problem in India, also contributing to one-fourth of the global MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fluoroquinolone (FQ) resistant leading to high pre-extensively drug-resistant (pre-XDR) and XDR-TB (further resistance against bedaquiline and/or linezolid) rates. Still, factors driving the MDR/pre-XDR epidemic in India are not well defined. METHODS: In a retrospective study, we analyzed 1852 consecutive MTBC strains obtained from patients from a tertiary care hospital laboratory in Mumbai by whole genome sequencing (WGS). Univariate and multivariate statistics was used to investigate factors associated with pre-XDR. Core genome multi locus sequence typing, time scaled haplotypic density (THD) method and homoplasy analysis were used to analyze epidemiological success, and positive selection in different strain groups, respectively. RESULTS: In total, 1016 MTBC strains were MDR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominant L2 (Beijing) strain clusters (Cl 1–3) representing half of the pre-XDR and 40% of the XDR-TB cases. L2 strains were associated with pre-XDR/XDR-TB (P < 0.001) and, particularly Cl 1–3 strains, had high first-line and FQ resistance rates (81.6–90.6%). Epidemic success analysis using THD showed that L2 strains outperformed L1, L3, and L4 strains in short- and long-term time scales. More importantly, L2 MDR and MDR + strains had higher THD success indices than their not-MDR counterparts. Overall, compensatory mutation rates were highest in L2 strains and positive selection was detected in genes of L2 strains associated with drug tolerance (prpB and ppsA) and virulence (Rv2828c). Compensatory mutations in L2 strains were associated with a threefold increase of THD indices, suggesting improved transmissibility. CONCLUSIONS: Our data indicate a drastic increase of FQ resistance, as well as emerging bedaquiline resistance which endangers the success of newly endorsed MDR-TB treatment regimens. Rapid changes in treatment and control strategies are required to contain transmission of highly successful pre-XDR L2 strains in the Mumbai Metropolitan region but presumably also India-wide. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-022-01076-0.
format Online
Article
Text
id pubmed-9394022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93940222022-08-23 High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region Dreyer, Viola Mandal, Ayan Dev, Prachi Merker, Matthias Barilar, Ivan Utpatel, Christian Nilgiriwala, Kayzad Rodrigues, Camilla Crook, Derrick W. Rasigade, Jean-Philippe Wirth, Thierry Mistry, Nerges Niemann, Stefan Genome Med Research BACKGROUND: Multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains are a serious health problem in India, also contributing to one-fourth of the global MDR tuberculosis (TB) burden. About 36% of the MDR MTBC strains are reported fluoroquinolone (FQ) resistant leading to high pre-extensively drug-resistant (pre-XDR) and XDR-TB (further resistance against bedaquiline and/or linezolid) rates. Still, factors driving the MDR/pre-XDR epidemic in India are not well defined. METHODS: In a retrospective study, we analyzed 1852 consecutive MTBC strains obtained from patients from a tertiary care hospital laboratory in Mumbai by whole genome sequencing (WGS). Univariate and multivariate statistics was used to investigate factors associated with pre-XDR. Core genome multi locus sequence typing, time scaled haplotypic density (THD) method and homoplasy analysis were used to analyze epidemiological success, and positive selection in different strain groups, respectively. RESULTS: In total, 1016 MTBC strains were MDR, out of which 703 (69.2%) were pre-XDR and 45 (4.4%) were XDR. Cluster rates were high among MDR (57.8%) and pre-XDR/XDR (79%) strains with three dominant L2 (Beijing) strain clusters (Cl 1–3) representing half of the pre-XDR and 40% of the XDR-TB cases. L2 strains were associated with pre-XDR/XDR-TB (P < 0.001) and, particularly Cl 1–3 strains, had high first-line and FQ resistance rates (81.6–90.6%). Epidemic success analysis using THD showed that L2 strains outperformed L1, L3, and L4 strains in short- and long-term time scales. More importantly, L2 MDR and MDR + strains had higher THD success indices than their not-MDR counterparts. Overall, compensatory mutation rates were highest in L2 strains and positive selection was detected in genes of L2 strains associated with drug tolerance (prpB and ppsA) and virulence (Rv2828c). Compensatory mutations in L2 strains were associated with a threefold increase of THD indices, suggesting improved transmissibility. CONCLUSIONS: Our data indicate a drastic increase of FQ resistance, as well as emerging bedaquiline resistance which endangers the success of newly endorsed MDR-TB treatment regimens. Rapid changes in treatment and control strategies are required to contain transmission of highly successful pre-XDR L2 strains in the Mumbai Metropolitan region but presumably also India-wide. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-022-01076-0. BioMed Central 2022-08-22 /pmc/articles/PMC9394022/ /pubmed/35989319 http://dx.doi.org/10.1186/s13073-022-01076-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dreyer, Viola
Mandal, Ayan
Dev, Prachi
Merker, Matthias
Barilar, Ivan
Utpatel, Christian
Nilgiriwala, Kayzad
Rodrigues, Camilla
Crook, Derrick W.
Rasigade, Jean-Philippe
Wirth, Thierry
Mistry, Nerges
Niemann, Stefan
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title_full High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title_fullStr High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title_full_unstemmed High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title_short High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region
title_sort high fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant l2 mycobacterium tuberculosis clones in the mumbai metropolitan region
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394022/
https://www.ncbi.nlm.nih.gov/pubmed/35989319
http://dx.doi.org/10.1186/s13073-022-01076-0
work_keys_str_mv AT dreyerviola highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT mandalayan highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT devprachi highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT merkermatthias highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT barilarivan highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT utpatelchristian highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT nilgiriwalakayzad highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT rodriguescamilla highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT crookderrickw highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT rasigadejeanphilippe highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT wirththierry highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT mistrynerges highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion
AT niemannstefan highfluoroquinoloneresistanceproportionsamongmultidrugresistanttuberculosisdrivenbydominantl2mycobacteriumtuberculosisclonesinthemumbaimetropolitanregion